Sarepta Therapeutics to Host Conference Call to Discuss Regulatory Update for Eteplirsen on Wednesday, July 24, 2013 at 8:00 AM EDT
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced it will hold a conference call at 8:00 a.m. EDT (5:00 a.m. PDT) on Wednesday, July 24, 2013, to provide a regulatory update for eteplirsen, its lead product candidate for the treatment of Duchenne muscular dystrophy (DMD).
The conference call may be accessed by dialing 800.446.2782 for domestic callers and 847.413.3235 for international callers. The passcode for the call is 35357086. Please specify to the operator that you would like to join the "Sarepta Therapeutics Regulatory Update Call." The conference call will be webcast live under the events section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sarepta.com.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.